The use of the molecular adsorbent recirculating system (MARS) albumin dialysis for the treatment of liver failure: a nursing perpective.
Albumin dialysis for the treatment of liver failure was introduced in Canada in 2006. At the London Health Sciences Centre, there have been seven patients treated with this therapy. A few other centres across Canada have started to use this complex therapy. This article includes an overview of liver failure and a description of the role of albumin dialysis in liver failure, the potential adverse effects of this therapy, and the impact of liver dialysis on the nursing care of this patient population.
McCready
Rachelle
R
London Health Sciences Centre, University Hospital, London, Ontario. Rachelle.McCready@lhsc.on.ca
D000418:Albumins / Q000627:therapeutic use*; D015314:Dialysis Solutions / Q000627:therapeutic use*; D006801:Humans; D017093:Liver Failure / Q000451:nursing* / Q000503:physiopathology; D019164:Liver, Artificial; D006435:Renal Dialysis / Q000295:instrumentation / Q000379:methods*
D000418:Albumins; D015314:Dialysis Solutions